WOCKPHARMA · Wockhardt Ltd · Biotechnology & Drugs
WOCKPHARMA · Wockhardt Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
19.6% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹929 Cr
Revenue YoY
PAT YoY
+217.8%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
16.3
P/S (TTM)
9.9
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| WOCKPHARMA (this stock) | 77 | 16.3 | +11.5% | +8.3% | 0.45 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 2q
MF
6.79% (-1.33pp)
falling 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-05-06 | WOCKPHARMA | 1009622 | 1 | WEAK | BULK |
News timeline
- lowthehindubusinessline.com· 03 Nov 2026, 09:38 amQ2 Results 03rd Nov Oct Live: SBI, NSE, Bajaj Finserv, Solar Ind, Fortis, Gujarat Fluoro, Bajaj Holdings, Lloyds Metals & Energy, Lupin, MCX, Emcure Pharma, AIA Engineering, Zydus Wellness to announce
- unknownthehindubusinessline.com· 12 Sept 2026, 08:42 pmBandu’s Blockbusters for September 13, 2026
- lowthehindubusinessline.com· 05 Sept 2026, 09:24 pmBandu’s Blockbusters for September 5, 2026
- lowlivemint.com· 27 Jul 2026, 04:35 pmHow three stubborn men, and $1.5 billion poured in over two decades, put India on the world’s new-drug map
Concalls & investor presentations
AI-generatedKey takeaway: The earnings call for Wockhardt Limited on June 4, 2026, featured management discussing the company's transformation and recent achievements, including the US FDA approval of Zaynich, the first Indian research product to receive such approval. Dr. Murtaza Khorakiwala highlighted the company's focus on profitability, reporting a top line of INR 3,373 crores and an EBITDA of INR 630 crores, with a significant increase in EBITDA margin from 5.4% to 18.6% over three years. The company aims to leverage its three business pillars: pharmaceuticals, biosimilars, and novel antibiotics. Management emphasized growth in emerging markets and the importance of operational excellence. The call also included discussions on the launch strategy for Zaynich in the US and India, with a focus on market access and clinical adoption. The leadership team was introduced, showcasing their expertise in the anti-infective space. The session concluded with a Q&A segment addressing various investor inquiries.
Management emphasized significant achievements and growth strategies.
Sourced from an exchange-filed transcript, dated 11 Jun 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Wockhardt Limited, dated June 4, 2026, outlined the company's strategic overview and growth drivers. Management reported a FY26 income of INR 3,373 Cr. and an EBITDA of INR 630 Cr., reflecting a 51% year-over-year growth in EBITDA. The presentation highlighted the successful performance of the novel antibiotic Emrok, which achieved approximately 50% growth, and the company's focus on high-margin core products. Wockhardt's foray into the US market with the antibiotic Zaynich was emphasized, showcasing its potential to address significant healthcare challenges related to antimicrobial resistance. The company also discussed its operational excellence initiatives, including cost management and supply chain optimization. Management set objectives for the next two years, focusing on growth acceleration and sustainable operational excellence, particularly in the biotech and pharmaceutical sectors.
Management emphasized strong financial performance and strategic growth initiatives.
Sourced from an exchange-filed presentation, dated 04 Jun 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedWockhardt Limited (WOCKPHARMA) reported total income of ₹3,484 crore and operating profit (EBITDA) of ₹630 crore for FY2025-26, with 78% international business contribution. The company emphasizes its focus on antibiotic research and combating antimicrobial resistance. The auditor highlighted key audit matters including revenue recognition and the recoverability of property, plant, equipment, and intangible assets. There are contingent liabilities related to tax disputes, including ₹345 crore disputed by the company with income tax authorities. The company has no defaults in loan repayments or interest payments, and no material changes post-FY2025-26. The net debt to equity ratio stands at 78%.
- Total income of ₹3,484 crore and operating profit (EBITDA) of ₹630 crore for FY2025-26.
- 78% international business contribution and focus on antibiotic research against antimicrobial resistance.
- Key audit matters include revenue recognition and recoverability of property, plant, equipment, and intangible assets.
- Contingent liabilities include ₹345 crore disputed with income tax authorities and ₹117 crore with sales tax (including GST) authorities.
- No defaults in loan repayments or interest payments, and no material changes post-FY2025-26.
Key takeaway: Wockhardt Limited reported strong financial performance with a focus on antibiotic innovation, but faces risks related to recoverability of significant assets and contingent liabilities from tax disputes.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (2 items); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceRecent (last 12 months)
The auditor states that there is no material uncertainty regarding the company's ability to meet its liabilities within one year, but clarifies this is not an assurance of future viability.
Regulatory Action
2 occurrencesEarlier (1-3 years ago)
The company received a show cause notice from SEBI under multiple regulations regarding events in 2013 and settled the matter by paying a determined amount, with the final settlement order passed on 22 May 2023.
BSE Limited levied a fine of ₹10,000 plus GST on the company for alleged delay in furnishing prior intimation about the meeting of the Board of Directors regarding change in terms of unlisted debentures.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
Merck Life Sciences Private Limited filed a company petition under IBC against Wockhardt for compensation of products ordered but not purchased, with the claim currently pending.
Routine disclosures
Internal Control Weakness
1 occurrenceRecent (last 12 months)
The company has identified a material weakness in its internal controls, which affects the reliability of financial reporting and the preparation of consolidated financial statements.
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has contingent liabilities including demands from Central Excise, Income Tax, Sales Tax (including GST), Service Tax, Municipal Corporation, and Differential Custom Duty authorities, with amounts ranging from ₹ 0.26 crore to ₹ 345 crore, all disputed by the company.
Earlier (1-3 years ago)
The company has contingent liabilities including demands from Central Excise, Income Tax, Sales Tax (including GST), Service Tax, Municipal Corporation, and others, with amounts ranging from ₹ 3 crore to ₹ 321 crore, all disputed by the company.
The company has contingent liabilities including demands from Central Excise, Income Tax, Sales Tax, Service Tax, and Municipal Corporation authorities, with amounts ranging from ₹ 3 crore to ₹ 546 crore, all disputed by the company.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
The company approved the appointment of Ms. Zahabiya Khorakiwala, a related party, as Executive Co-chairperson of its subsidiary Wockhardt Bio AG with an annual remuneration of USD 250,000.
Earlier (1-3 years ago)
The company has a related-party transaction involving a contract manufacturing agreement where inventory was purchased, but the customer did not fulfill contractual obligations, leading to a provision of ₹ 14 crore.
The company has related-party transactions with its subsidiaries and a promoter-controlled NBFC for funding, exceeding 10% of consolidated annual turnover, requiring shareholder approval.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
14.92% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).